Biomedical & Biotech News
Clinical progress, drug development, platform technologies, and regulatory moves.
BNT113 combined with immunotherapy did not significantly extend the time before patients’ disease progressed. The trial will continue to address another key question: whether this combination can help patients live longer.
A licensing deal worth up to $1.16 billion turns obesity drug development’s attention to fat cells themselves. The concept of selectively reducing visceral fat while preserving lean tissue still awaits validation in human studies.
Nearly 450,000 cells reveal multiple evolutionary paths within pancreatic cancer. The study links changes in MYC to more aggressive cell states and reverses some features in experiments, offering clues for treatment research.
Patients whose disease continues to progress after prior radionuclide therapy may gain another treatment option. RYZ101 has met its primary progression-free survival endpoint, but the magnitude of benefit and detailed safety data have not yet been released, leaving key information needed to establish its clinical value.
Turning tissue images into reliable evidence for drug development requires more than algorithms. This collaboration links AI analysis with specimen processing, but the announcement provides no new validation results showing whether it can improve reproducibility or help interpret treatment efficacy.
More than 300 million laboratory test records map physiological shifts around menopause, while sparking debate over whether the “cliff” metaphor is appropriate. The association between hormone therapy and smaller changes remains to be clarified in clinical trials.
A new study in mice offers mechanistic clues to how a protein limits the continued release of inflammatory signals by T cells. Cell data from patients with ulcerative colitis also show related changes, but whether this regulatory pathway can be translated into treatment remains to be verified.
A trial involving several ultra-rare cholestatic liver diseases provides new evidence for relieving itching in children. Mirum plans to apply to expand the drug’s U.S. indications in the first half of 2027, but diarrhea rates and long-term efficacy remain key considerations.
AviadoBio reports progress in the early AVB-101 trial, with increased cerebrospinal fluid progranulin concentrations in higher-dose cohorts. This offers clues about whether the treatment produces its intended biological effect, but key evidence is still needed to demonstrate that it can slow dementia.
A four-hospital study used ultrasound videos to identify suspicious breast lesions, with junior physicians’ accuracy rising from 66.7% to 89.2% with AI assistance. The findings provide evidence for assisted interpretation, but further clinical validation is needed before biopsies can be safely reduced.
A small trial has yielded signs of improvement in both intestinal tissue and symptoms. The CD122 antibody ANB033 outperformed placebo during a gluten challenge, but larger studies are needed to determine whether short-term protection can translate into long-term benefits in daily life.
The pivotal trial of laru-zova showed that about one-quarter to one-third of treated participants met the prespecified threshold for improvement in low-light vision after one year. This progress brings the therapy closer to a marketing application while highlighting the importance of patient selection, surgical risks, and long-term follow-up.
The alliance combines funding, exclusive U.S. sales rights, and a future acquisition option in a single arrangement. Versius could expand its market through a major medical device company's hospital network, but the transaction remains subject to approval, and the price of a full acquisition has not been disclosed.